Background: Diffuse large B-cell lymphoma (DLBCL) is the most frequent subtype of nonHodgkin's lymphoma globally with frequent extra nodal involvement. There is sporadic data available on thyroid DLBCL in Indian population and hence we undertook this retrospective observational study at Kidwai Memorial Institute of Oncology, a tertiary care oncology center in India to analyze the clinico biological features of this disease. Methodology: A total of 7 consecutive cases diagnosed as DLBCL by appropriate lymph node biopsy with evidence of thyroid involvement on fine-needle aspiration cytology of thyroid or thyroid histopathology (following thyroidectomy) were confirmed by immunohistochemistry (WHO classification) between January 2008 and September 2013 were included in this study. Results: A total of 7 patients were included in the study. Median age was 65-years (range: 50-72 years), and all were females. Six out of seven were in stage IIAE and one was in stage IVAE. The distribution according to the international prognostic index was as follows: 3 were in low risk, 1 in low-intermediate, 2 in high-intermediate and 1 in high risk group. Regarding treatment, 5 received CHOP, 1 received COP and 1 received no treatment. 5 patients received radiotherapy. 2 patients underwent subtotal thyroidectomy. Of the 6 patients who received chemotherapy ± radiotherapy, 4 had complete response, 2 had partial response. The median survival was 15 months (3-32 months). Conclusions: Extranodal thyroid DLBCL presents common in elderly age group and in females. A multimodality treatment approach is used to treat this entity and may improve survival compared with unimodality approach.
INTRODUCTION
The global burden of nonHodgkin's lymphoma (NHL) has been steadily increasing over the last two decades and India is no exception with NHL causing significant morbidity and mortality. [1] Around 25% of NHL arise in tissues other than the lymph node, spleen, Waldeyer's ring and thymus, and are referred to as primary extra nodal NHL (EN-NHL). It has been observed that the incidence of EN-NHL has increased more rapidly than the nodal type. [2] Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of NHL worldwide and aggressive, high grade lymphoma with a rapid onset and progression. About one-third of DLBCLs has a primary EN origin. [3] Primary thyroid lymphoma (PTL) is a rare disease, accounting for ~5% of all thyroid malignancies and approximately 3% of all lymphomas and 7% of extranodal lymphomas. More than 75% of thyroid lymphomas are constituted by DLBCL. [4] There is sporadic data from India and hence we undertook this retrospective study in India.
METHODOLOGY
This was a retrospective observational study carried out at Kidwai Memorial Institute of Oncology, a tertiary care center in India. Diagnosis of thyroid DLBCL was made by appropriate lymph node biopsy with evidence of thyroid involvement on fine-needle aspiration cytology of thyroid or thyroid histopathology (following thyroidectomy) confirmed by immunohistochemistry (WHO classification) 
RESULTS
A total of 7 patients with thyroid DLBCL were included in the study [ Table 1 ]. Median age was 65-year (range: 50-72 years), and all were females. 6 out of seven were in stage IIAE and one was in stage IVAE. The distribution according to the IPI was the following: 3 were in low risk, 1 in low-intermediate, 2 in high-intermediate, and 1 in high risk group. Regarding treatment, 5 received CHOP, 1 received COP and 1 received no treatment. 2 patients underwent subtotal thyroidectomy. 5 received radiotherapy. Of the 6 patients who received chemotherapy ± radiotherapy, 4 had complete response, 2 had partial response. The median OS was 15 months (range 3-32 months).
DISCUSSION
Primary thyroid lymphoma is an unusual entity, comprising of around 5% of all thyroid malignancies, 1-3% of lymphomas and 2.5-7% of EN lymphomas. [4] Dawson et al. defined primary EN-NHL as the site restricted to lymphomas that present with the main manifestation of their disease at that site, with or without regional lymph node involvement. [5] Primary EN lymphomas of thyroid include Stage I or II disease, but Stage III or IV disease were also included if symptoms and signs of thyroid involvement are evident, as also seen in one of our patients. PTL usually affects middle aged and elderly women with a peak incidence between 60 and 69 years and there was a female preponderance. [6] [7] [8] In our series, the median age was 65-year with all being females. Most patients present without B symptoms as also seen in our study where 6 out of 7 had no B symptoms. [9] The risk of PTL is higher in those with preexisting Hashimoto's thyroiditis. [10] In our study, 3 out of 7 (42.8%) patients had a diagnosis of hashimoto's thyroiditis prior to developing PTL. Though, mucosa associated lymphoid tissue (MALT) is the most common lymphoma accounting in patients with hashimotos thyroiditis, in our series all three patients were cases of DLBCL thyroid. Around two-third of patients with PTL have antithyroid antibodies. [8] Three fourths of thyroid lymphomas are B-cell NHL. Hodgkin's and T-cell lymphomas are unusual. [10, 11] Among the B-cell lymphomas, DLBCL accounts for more than three fourths of the cases, others being MALT and follicular lymphoma. [12] Wang et al. reported five cases of Hodgkin's lymphoma who were treated with combination chemotherapy and surgery. [12, 13] The most common presenting symptoms in our series was thyroid enlargement with cervical lymphadenopathy (100%). However, three patients (42.8%) presented with compressive symptoms-hoarseness, dyspnea and dysphagia. This is on par with other studies including an Indian study published recently by Kumar et al. who also made a similar observation.
[13] The It has the capability of masquerading as thyroid carcinoma, especially anaplastic histopathology. Treatment for aggressive lymphomas involves a multi-modality approach involving chemotherapy and IFRT. As this entity is quite uncommon, very few studies are found on the literature search [ Table 2 ]. The largest study so far was the one reported by Graff-Baker et al. in 2009, [16] where PTL patients were identified in the SEER database. Of the 1408 patients who were identified over 32-year of follow-up, median age was 66-year with three fourths being females and 68% with DLBCL histology. In this study, advanced age, stage, DLBCL histology and no radiation/surgery were adverse prognostic factors. Aggressive lymphomas of the thyroid like DLBCL require a multimodality treatment strategy involving chemotherapy, ± surgery and radiation therapy as also seen in the Indian study by Ritesh et al. [13] who reported a 5-year OS of 41%, which was probably less compared to other studies. The reasons cited by the authors were advanced stage and age. Various other studies have reported superior efficacy of chemotherapy with radiation therapy. Matsuzuka et al. [18] reported a 100% OS rate at 8-year. Ha et al. in 2001 showed 5-year OS and disease free survival (DFS) of 64% and 76% with combined modality. [19] Niitsu et al. in 2007 reported 32 cases of DLBCL thyroid and their results showed a 5-year OS was 90.3% and the 5-year DFS was 84.3% (18 had stage IE and 14 IIE). [17] In our study, five patients received combined chemotherapy and radiation therapy and hence had a better survival compared to others [ Table 1 ].
To conclude PTL is more common in elderly age group and in females. The index of suspicion with appropriate biopsy with immunohistochemistry is required for early diagnosis. The treatment with multimodality treatment with anthracycline based chemotherapy, with/out surgery with radiotherapy may improve the survival.
We have compared our study with a large study by Baker et al. of >1400 patients. [16] The strengths of our study include one of the few reports from India and limitations include a short follow-up and rather small case series. This study per say does suggest that more studies on this entity are required, and a multi-modality approach is required to treat this condition. Moreover, a high index of suspicion is required to diagnose this PTL when a thyromegaly is observed. [16] 1408 68% DLBCL 10% FL, 10% marginal zone, and 3% small lymphocytic 
